(Q34210693)

31 July 2017

1 reference

title

Predictors of a favorable response to alpha interferon therapy for hepatitis C. (English)

1 reference

31 July 2017

Barnes E

1

1 reference

31 July 2017

Webster G

series ordinal

2

1 reference

31 July 2017

Whalley S

series ordinal

3

1 reference

31 July 2017

Dusheiko G

series ordinal

4

1 reference

31 July 2017

publication date

1 November 1999

1 reference

31 July 2017

published in

Clinics in liver disease

1 reference

31 July 2017

volume

3

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

775-791

1 reference

Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Iron and chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Measurements of iron status in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Interferon treatment of cirrhotic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Differential sensitivity of hepatitis C virus quasispecies to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Characterization of the 5′ noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Response to interferon alpha therapy is influenced by the iron content of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970238-5

7 January 2021

10.1016/S1089-3261(05)70238-5

Identifiers

DOI

1 reference

31 July 2017

1 reference